Silicone breast implant research on local effects should be "top priority" -- FDA study authors.
This article was originally published in The Gray Sheet
Executive Summary
SILICONE BREAST IMPLANT RUPTURE IMPROVED TEST METHODS NEEDED to provide "more information on rates of rupture in general and the influence of rupture on other local and systemic complications," FDA scientist Barbara Silverman, MD, et al. say in a literature review appearing in the April 15 issue of Annals of Internal Medicine. The article says that information on local effects of the implants, such as rupture, capsular contracture and silicone migration, should be "a top priority on the research agenda."
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.